The new vaccine is indicated for individuals who have been previously vaccinated with any COVID-19 vaccine and are 65 years or older, or 12 to 64 years of age with at least 1 underlying condition that ...

In a crucial development, the FDA has approved Moderna's new COVID-19 vaccine designed specifically for high-risk Americans.

The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused ...

Moderna (NASDAQ: MRNA) stock represented the ticket to an investing win. The company brought its coronavirus vaccine from ...

US growth likely to slow to 1.6% this year, hobbled by Trump's trade wars, OECD says. U.S. economic growth will slow to 1.6% this year from 2.8% last year as President ...

U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said on Tuesday that Moderna has agreed to a true ...

The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to ...

The World Health Organization has tracked a new COVID-19 variant that has emerged across multiple region. Amid this, the Food ...

The FDA is defending a decision to restrict access to a newly-approved low dose COVID vaccine from Moderna that the company says could be a game changer. FOX's Jared Halpern reports.

Moderna, over the weekend, announced that the U.S. Food and Drug Administration had approved its second-generation COVID ...

The FDA approved Moderna’s lower-dose COVID-19 vaccine, but only for individuals aged 65 years or older and people aged 12 to ...

Moderna's (MRNA) new COVID vaccine approval targets a broader high-risk population. Check out why I see potential for a 25-40 ...